NO892136L - Fremgangsmaate for fremstilling av nye peptider. - Google Patents

Fremgangsmaate for fremstilling av nye peptider.

Info

Publication number
NO892136L
NO892136L NO89892136A NO892136A NO892136L NO 892136 L NO892136 L NO 892136L NO 89892136 A NO89892136 A NO 89892136A NO 892136 A NO892136 A NO 892136A NO 892136 L NO892136 L NO 892136L
Authority
NO
Norway
Prior art keywords
procedure
preparation
new peptides
peptides
new
Prior art date
Application number
NO89892136A
Other languages
English (en)
Other versions
NO892136D0 (no
Inventor
Richard Himmelsbach
John Cooke Hodges
James Stanley Kaltenbronn
William Chester Patt
Joseph Thomas Repine
Ila Sircar
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO892136D0 publication Critical patent/NO892136D0/no
Publication of NO892136L publication Critical patent/NO892136L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
NO89892136A 1988-05-27 1989-05-26 Fremgangsmaate for fremstilling av nye peptider. NO892136L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19999088A 1988-05-27 1988-05-27
US07/321,638 US5036053A (en) 1988-05-27 1989-03-15 Diol-containing renin inhibitors

Publications (2)

Publication Number Publication Date
NO892136D0 NO892136D0 (no) 1989-05-26
NO892136L true NO892136L (no) 1989-11-28

Family

ID=26895354

Family Applications (1)

Application Number Title Priority Date Filing Date
NO89892136A NO892136L (no) 1988-05-27 1989-05-26 Fremgangsmaate for fremstilling av nye peptider.

Country Status (11)

Country Link
US (1) US5036053A (no)
EP (1) EP0343654A3 (no)
JP (1) JPH0267297A (no)
KR (1) KR900018137A (no)
AU (1) AU625456B2 (no)
DK (1) DK258589A (no)
FI (1) FI892521L (no)
NO (1) NO892136L (no)
NZ (1) NZ229281A (no)
PH (1) PH26816A (no)
PT (1) PT90659B (no)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326364B1 (en) * 1988-01-26 1994-06-22 Sankyo Company Limited Renin inhibitory oligopeptides, their preparation and use
US5238923A (en) * 1989-05-26 1993-08-24 Warner-Lambert Company Amino-substituted heterocycles as renin inhibitors
IE68045B1 (en) * 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
WO1993006127A1 (en) * 1991-09-17 1993-04-01 Warner-Lambert Company Novel amino acid prodrug renin inhibitors
US5223535A (en) * 1991-10-29 1993-06-29 G. D. Searle & Co. Propargyl glycine amino propargyl diol compounds for treatment of hypertension
US5227401A (en) * 1991-10-29 1993-07-13 G. D. Searle & Co. Ethynyl alanine amino diol compounds for treatment of hypertension
EP0539976A1 (en) * 1991-10-29 1993-05-05 G.D. Searle & Co. Ethynyl-alanine-amino-diol compounds for treatment of hypertension
CA2127456A1 (en) * 1992-02-13 1993-08-19 Warner-Lambert Company Llc Process for preparing chiral ethyl (5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl) carbamate
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5252591A (en) 1992-08-14 1993-10-12 G. D. Searle & Company Pyridinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension
US5373017A (en) * 1992-08-14 1994-12-13 G. D. Searle & Co. Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension
US5298505A (en) * 1992-08-14 1994-03-29 G. D. Searle & Co. Ethynyl alanine amino diol compounds having a piperazinyl-terminated group or a piperazinyl-alkylamino-terminated group for treatment of hypertension
US6376506B1 (en) 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
US6493178B1 (en) * 1997-04-30 2002-12-10 Spectra Logic Corporation Data cartridge library system
US6423688B1 (en) * 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6130220A (en) * 1997-10-16 2000-10-10 Syntex (Usa) Inc. Sulfamide-metalloprotease inhibitors
US6407124B1 (en) 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
US6410746B1 (en) 1999-04-27 2002-06-25 Research Foundation Of State University Of New York, The Metal cataltsts and methods for making and using same
ATE532070T1 (de) 2000-12-14 2011-11-15 Brigham & Womens Hospital Entzündungsmarker zum nachweis und zur prävention von diabetes mellitus
AU2002331753A1 (en) 2001-08-27 2003-03-10 The Research Foundation Of State University Of New York Dirhodium catalyst compositions and methods for using same
US6962891B2 (en) 2001-08-27 2005-11-08 The Research Foundation Of State University Of New York Solid support dirhodium catalyst compositions and methods for making and using same
PT3072978T (pt) 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 como um marcador de doença cardiovascular
US7273616B2 (en) * 2002-05-10 2007-09-25 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating Varicella zoster virus and methods of use thereof
EP1670459A4 (en) * 2003-08-20 2009-03-25 Nitromed Inc NITROSED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND APPLICATION METHODS
JP2007504136A (ja) * 2003-08-28 2007-03-01 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化利尿化合物、組成物、ならびに使用方法
DK2384753T3 (en) 2003-08-29 2016-04-11 Brigham & Womens Hospital Hydantoin derivatives as inhibitors of cell necrosis
ATE546734T1 (de) 2003-12-05 2012-03-15 Cleveland Clinic Foundation Risikomarker für eine herzkreislaufkrankheit
US20090131342A1 (en) * 2004-01-22 2009-05-21 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
CA2624601C (en) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
US20080275093A1 (en) * 2004-11-15 2008-11-06 Nitromed, Inc. Diuretic Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use
CA2595579A1 (en) * 2005-01-21 2006-07-27 Nitromed, Inc. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
JP2008528626A (ja) * 2005-01-31 2008-07-31 マイラン ラボラトリーズ インク． ヒドロキシル化されたネビボロールを含む薬学的組成物
EP1858525A2 (en) * 2005-02-16 2007-11-28 Nitromed, Inc. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
WO2006093864A1 (en) * 2005-02-28 2006-09-08 Nitromed, Inc. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
WO2006099058A2 (en) * 2005-03-09 2006-09-21 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
KR101310037B1 (ko) 2005-05-31 2013-09-24 밀란 인크. 네비볼롤을 함유하는 조성물
US7700798B1 (en) 2005-06-08 2010-04-20 The Research Foundation Of State University Of New York Erogorgiaene congeners and methods and intermediates useful in the preparation of same
US7816536B2 (en) * 2005-06-10 2010-10-19 The Research Foundation Of State University Of New York 4-substituted and 7-substituted indoles, benzofurans, benzothiophenes, benzimidazoles, benzoxazoles, and benzothiazoles and methods for making same
WO2007016677A2 (en) 2005-08-02 2007-02-08 Nitromed, Inc. Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
US20090054381A1 (en) * 2005-10-04 2009-02-26 Nitromed, Inc. Methods for treating respiratory disorders
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
WO2007059311A2 (en) * 2005-11-16 2007-05-24 Nitromed, Inc. Furoxan compounds, compositions and methods of use
US7385064B1 (en) 2005-11-30 2008-06-10 The Research Foundation Of State University Of New York Catalysts for use in enantioselective synthesis
WO2007075542A2 (en) * 2005-12-22 2007-07-05 Nitromed, Inc. Nitric oxide enhancing pyruvate compounds, compositions and methods of use
CA2659082A1 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
EP2081892A4 (en) 2006-11-17 2014-03-05 Donald F Weaver COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE
BRPI0810409A2 (pt) 2007-04-18 2015-02-18 Thethys Bioscience Inc Biomarcadores relacionados ao diabetes e métodos de uso destes
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
US8741910B2 (en) 2008-11-25 2014-06-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2373630A1 (en) 2008-12-05 2011-10-12 Merck Sharp & Dohme Corp. Nitrooxy derivatives as angiotensin ii receptor antagonists
JP5075145B2 (ja) 2009-02-13 2012-11-14 トヨタ自動車株式会社 内燃機関の制御装置
CN102414194A (zh) 2009-02-26 2012-04-11 默沙东公司 可溶性鸟苷酸环化酶激活剂
TW201201764A (en) 2010-02-01 2012-01-16 Hospital For Sick Children Remote ischemic conditioning for treatment and prevention of restenosis
SG10201908570RA (en) 2010-03-31 2019-11-28 Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
WO2011146371A1 (en) 2010-05-21 2011-11-24 Merck Sharp & Dohme Corp. Diazeniumdiolate cyclohexyl derivatives
RU2013124814A (ru) 2010-10-29 2014-12-10 Мерк Шарп Энд Домэ Корп. Гетероциклические производные диазенийдиолата
ES2618812T3 (es) 2011-01-20 2017-06-22 Merck Sharp & Dohme Corp. Antagonistas del receptor mineralocorticoide
JO3350B1 (ar) 2011-03-07 2019-03-13 Merck Sharp & Dohme مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
WO2012139495A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
WO2012148808A1 (en) 2011-04-26 2012-11-01 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
US9272987B2 (en) 2011-05-02 2016-03-01 Merck Sharp & Dohme Corp. Diazeniumdiolate cyclohexyl derivatives
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
WO2013066714A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013066717A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
CN104640856B (zh) 2012-05-11 2017-09-15 复位治疗公司 作为隐花色素调节剂的含有咔唑的磺酰胺类
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
WO2014022195A1 (en) 2012-08-01 2014-02-06 Tavakoli Zahra Free flowing, frozen compositions comprising a therapeutic agent
WO2014085210A1 (en) 2012-11-29 2014-06-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2934518B1 (en) 2012-12-19 2020-02-19 Merck Sharp & Dohme Corp. Spirocyclic cetp inhibitors
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
EP3079701B1 (en) 2013-12-11 2021-08-11 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2015088886A1 (en) 2013-12-11 2015-06-18 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP3083573B1 (en) 2013-12-18 2024-08-07 Merck Sharp & Dohme LLC Inhibitors of the renal outer medullary potassium channel
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
WO2015183938A1 (en) 2014-05-29 2015-12-03 Geneticure Llc Improved therapeutic regimen for hypertension
WO2016018729A1 (en) 2014-07-29 2016-02-04 Merck Sharp & Dohme Corp. Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
EP3212226B1 (en) 2014-10-31 2020-03-18 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
EP3303342B1 (en) 2015-05-27 2021-03-17 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
EP3310782B1 (en) 2015-05-28 2021-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
EP3322420B1 (en) 2015-07-13 2021-12-29 Merck Sharp & Dohme Corp. Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
WO2017197555A1 (en) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
WO2020236690A1 (en) 2019-05-22 2020-11-26 Merck Sharp & Dohme Corp. Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
WO2020236688A1 (en) 2019-05-22 2020-11-26 Merck Sharp & Dohme Corp. Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
ES3048448T3 (en) 2020-07-22 2025-12-10 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
US12286429B2 (en) 2021-07-22 2025-04-29 Janssen Pharmaceutica Nv 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845079A (en) * 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
ES2066755T3 (es) * 1986-06-10 1995-03-16 Merck Patent Gmbh Derivados de aminoacidos inhibidores de renina.

Also Published As

Publication number Publication date
FI892521A7 (fi) 1989-11-28
KR900018137A (ko) 1990-12-20
PT90659B (pt) 1994-10-31
JPH0267297A (ja) 1990-03-07
EP0343654A3 (en) 1991-05-29
DK258589A (da) 1989-11-28
FI892521A0 (fi) 1989-05-24
AU3463389A (en) 1989-11-30
NO892136D0 (no) 1989-05-26
PT90659A (pt) 1989-11-30
PH26816A (en) 1992-11-05
US5036053A (en) 1991-07-30
FI892521L (fi) 1989-11-28
DK258589D0 (da) 1989-05-26
AU625456B2 (en) 1992-07-09
NZ229281A (en) 1991-11-26
EP0343654A2 (en) 1989-11-29

Similar Documents

Publication Publication Date Title
NO892136D0 (no) Fremgangsmaate for fremstilling av nye peptider.
NO885454D0 (no) Fremgangsmaate for fremstilling av triklormonosilan.
NO894210D0 (no) Fremgangsmaate for fremstilling av kinolyloxazol-2-oner.
NO904059D0 (no) Fremgangsmaate for fremstilling av nye substituerte isokinoliner.
NO894649L (no) Fremgangsmaate for fremstilling av (s)-alfa-ethyl-2-oxo-1-pyrrolidinacetamid.
NO901813D0 (no) Fremgangsmaate for fremstilling av nye tieno-triazolo-diazepin-derivater.
NO895032D0 (no) Fremgangsmaate for fremstilling av 2-benzotiazoliner.
NO913391D0 (no) Fremgangsmaate for fremstilling av nye hetrazepinoide syreamider.
NO890159L (no) Fremgangsmaate for fremstilling av 1-alkyl-5-nitroimidazoler.
NO893794D0 (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO892977L (no) Fremgangsmaate for fremstilling av nye s-adenosylmethionin-derivater.
NO904069D0 (no) Fremgangsmaate for fremstilling av nye alkanofenoner.
NO891574L (no) Fremgangsmaate for fremstilling av farmasoeytisk anvendbareforbindelser.
NO911118D0 (no) Fremgangsmaate for fremstilling av nye 8-sulfamylmethylen-2-amino-tetraliner.
NO895040D0 (no) Fremgangsmaate for fremstilling av polyhydroxybenzyloxypropanolaminer.
NO891025L (no) Fremgangsmaate for fremstilling av nye, terapeutisk aktivesialosylglycerider.
NO894967D0 (no) Fremgangsmaate for fremstilling av nye thrombolytiske proteiner.
NO893006D0 (no) Fremgangsmaate for fremstilling av nye allylaminoetylazoler
NO893796D0 (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO893795L (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO902293L (no) Fremgangsmaate for fremstilling av nye tiazepinderivater.
NO901401D0 (no) Fremgangsmaate for fremstilling av nye 1-difenylmethylpiperidinderivater.
NO902967L (no) Fremgangsmaate til fremstilling av nye sulfamoyl-tiofener.
NO882172L (no) Fremgangsmaate ved fremstilling av nye indansulfonamider.
NO890819L (no) Fremgangsmaate for fremstilling av hydroksybenzaldehyder.